Menu
  • Home
  • Contact
  • News & Publications
  • Strategy
  • Technology
    • Technology
    • Frequently Asked Questions
  • Pipeline
  • Partnering
  • Company
    • About Us
    • Management Team
    • Board of Directors
    • Scientific Advisors
  • Home
  • Contact
  • News & Publications
  • Strategy
  • Technology
    • Technology
    • Frequently Asked Questions
  • Pipeline
  • Partnering
  • Company
    • About Us
    • Management Team
    • Board of Directors
    • Scientific Advisors

News & Publications

Other Publications

  • September 21, 2018 ACCEL Technology Platform – CAR TCR Summit 2018
  • August 31, 2018 FOCIS (Federation of Clinical Immunology Societies) 2018 Poster
  • November 1, 2017 Bay Area's AvidBiotics Splits Into Two Biotech Companies

Press Releases

  • October 24, 2019 Xyphos Biosciences and Gladstone Institutes Announce Publication Demonstrating convertibleCAR® Cells and Bispecific Broadly Neutralizing Antibodies Reduce Latent HIV Reservoir
  • April 16, 2019 Key Patent Issued for Xyphos Biosciences’ ACCEL™ Technology Platform
  • October 18, 2018 The Parker Institute for Cancer Immunotherapy Partners with Xyphos Biosciences to Develop Universal Programmable CAR-T Cells for Cancer Treatment
  • July 3, 2018 Xyphos Biosciences Names Thorsten Melcher, Ph.D., as Chief Business Officer
2019 © Xyphos